Zongpai Zhang, Jingpu Wu, Puyang Wang, Keyi Chai, Shanshan Jiang, Chiadi U Onyike, Gwenn S Smith, Jinyuan Zhou
{"title":"Deep Learning-based Synthesis of Amyloid PET Images from Structural MRI in Alzheimer's Disease.","authors":"Zongpai Zhang, Jingpu Wu, Puyang Wang, Keyi Chai, Shanshan Jiang, Chiadi U Onyike, Gwenn S Smith, Jinyuan Zhou","doi":"10.1007/s11307-026-02145-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Rationale: </strong>Amyloid-beta (Aβ) plaques in Alzheimer's disease (AD) are commonly imaged with specific PET radiotracers. To overcome the cost and availability limitations of PET, developing a more accessible diagnostic tool is essential. This study aimed to develop a deep-learning model that can synthesize Aβ-PET images from widely available MRI scans.</p><p><strong>Methods: </strong>The study utilized 431 subjects with both structural MRI and Aβ-PET scans from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including 213 cognitively normal (CN), 180 mild cognitive impairment (MCI), and 38 AD dementia cases. A specialized Vector Quantized Generative Adversarial Network (VQGAN) framework has been trained to generate Aβ-PET images from MRI features, utilizing datasets from patients across various stages of AD spectrum. A paired t-test was used to compare synthetic and real Aβ-PET scans, while an ANOVA was performed to evaluate standardized uptake value ratio differences among the CN, MCI, and AD dementia groups.</p><p><strong>Results: </strong>The synthesized Aβ-PET images closely resemble real Aβ-PET scans in terms of regional Aβ distribution, accurately capturing disease-stage characteristics across the AD spectrum. In three key cortical brain regions (frontal cortex, lateral temporal lobe, and posterior cingulate cortex and precuneus), the synthetic images have successfully replicated disease-related Aβ trends, showing statistically significant group differences (p < 0.05). Quantitative evaluation has confirmed the superiority of VQGAN over other models (lower MAE, higher PSNR/SSIM), demonstrating minimized errors, reduced noise, and better structural fidelity in synthesized images.</p><p><strong>Conclusion: </strong>This technology potentially offers a cost-effective, non-invasive alternative method for AD diagnosis and staging.</p>","PeriodicalId":18760,"journal":{"name":"Molecular Imaging and Biology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Biology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11307-026-02145-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Rationale: Amyloid-beta (Aβ) plaques in Alzheimer's disease (AD) are commonly imaged with specific PET radiotracers. To overcome the cost and availability limitations of PET, developing a more accessible diagnostic tool is essential. This study aimed to develop a deep-learning model that can synthesize Aβ-PET images from widely available MRI scans.
Methods: The study utilized 431 subjects with both structural MRI and Aβ-PET scans from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including 213 cognitively normal (CN), 180 mild cognitive impairment (MCI), and 38 AD dementia cases. A specialized Vector Quantized Generative Adversarial Network (VQGAN) framework has been trained to generate Aβ-PET images from MRI features, utilizing datasets from patients across various stages of AD spectrum. A paired t-test was used to compare synthetic and real Aβ-PET scans, while an ANOVA was performed to evaluate standardized uptake value ratio differences among the CN, MCI, and AD dementia groups.
Results: The synthesized Aβ-PET images closely resemble real Aβ-PET scans in terms of regional Aβ distribution, accurately capturing disease-stage characteristics across the AD spectrum. In three key cortical brain regions (frontal cortex, lateral temporal lobe, and posterior cingulate cortex and precuneus), the synthetic images have successfully replicated disease-related Aβ trends, showing statistically significant group differences (p < 0.05). Quantitative evaluation has confirmed the superiority of VQGAN over other models (lower MAE, higher PSNR/SSIM), demonstrating minimized errors, reduced noise, and better structural fidelity in synthesized images.
Conclusion: This technology potentially offers a cost-effective, non-invasive alternative method for AD diagnosis and staging.
期刊介绍:
Molecular Imaging and Biology (MIB) invites original contributions (research articles, review articles, commentaries, etc.) on the utilization of molecular imaging (i.e., nuclear imaging, optical imaging, autoradiography and pathology, MRI, MPI, ultrasound imaging, radiomics/genomics etc.) to investigate questions related to biology and health. The objective of MIB is to provide a forum to the discovery of molecular mechanisms of disease through the use of imaging techniques. We aim to investigate the biological nature of disease in patients and establish new molecular imaging diagnostic and therapy procedures.
Some areas that are covered are:
Preclinical and clinical imaging of macromolecular targets (e.g., genes, receptors, enzymes) involved in significant biological processes.
The design, characterization, and study of new molecular imaging probes and contrast agents for the functional interrogation of macromolecular targets.
Development and evaluation of imaging systems including instrumentation, image reconstruction algorithms, image analysis, and display.
Development of molecular assay approaches leading to quantification of the biological information obtained in molecular imaging.
Study of in vivo animal models of disease for the development of new molecular diagnostics and therapeutics.
Extension of in vitro and in vivo discoveries using disease models, into well designed clinical research investigations.
Clinical molecular imaging involving clinical investigations, clinical trials and medical management or cost-effectiveness studies.